Skip to Main Content

2021 STAT Summit

nov 16-18hybrid event

About

Charting a course for medicine's future

Leading figures in science and medicine joined us at the 2021 STAT Summit. Corporate executives, top scientists, patient advocates, and government officials had spirited discussions with each other, and with STAT’s award-winning reporters. They answered your questions and dove deep into the hottest topics in biotech, medicine, and policy.

The 2021 STAT Summit is complete

Thank you to the speakers and to all who tuned into our annual flagship Summit event. Be sure to catch up with coverage from the event, and learn more about all of our upcoming Summits.

Speakers

Learn from authoritative speakers

Apply today to be considered for speaking opportunities for future events.

Amy P. Abernethy, M.D., Ph.D.

Amy P. Abernethy, M.D., Ph.D.

President of Clinical Studies Platforms, Verily; Former Principal Deputy Commissioner, FDA

Blythe Adamson, Ph.D., MPH

Blythe Adamson, Ph.D., MPH

Founder and Epidemiologist, Infectious Economics, LLC; Covid Sports and Society Working Group

Noubar Afeyan, Ph.D.

Noubar Afeyan, Ph.D.

Founder and CEO, Flagship Pioneering; Co-Founder & Chairman, Moderna

Liz Barrett
Sponsor Speaker

Liz Barrett

President and Chief Executive Officer, UroGen Pharma

Trevor Bedford, Ph.D.

Trevor Bedford, Ph.D.

Associate Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Affiliate Faculty, the University of Washington

Rick Berke
STAT MODERATOR

Rick Berke

Co-Founder & Executive Editor, STAT

Sangeeta N. Bhatia, M.D., Ph.D.

Sangeeta N. Bhatia, M.D., Ph.D.

John J. and Dorothy Wilson Professor, Massachusetts Institute of Technology; Heath Sciences & Technology / Electrical Engineering & Computer Science, Howard Hughes Medical Institute; Director, Marble Center for Cancer Nanomedicine at the Koch Institute for Integrated Cancer Research

Elisabeth Bik, Ph.D.

Elisabeth Bik, Ph.D.

Science Integrity Consultant

Teresa Bitetti
Sponsor Speaker

Teresa Bitetti

President, Global Oncology Business Unit, Takeda

Eric Boodman
STAT MODERATOR

Eric Boodman

General Assignment Reporter, STAT

Albert Bourla, DVM, Ph.D.

Albert Bourla, DVM, Ph.D.

Chairman and Chief Executive Officer, Pfizer

Helen Branswell
STAT Moderator

Helen Branswell

Senior Writer, Infectious Disease, STAT

David Chang, M.D., Ph.D.
Sponsor Speaker

David Chang, M.D., Ph.D.

President, Chief Executive Officer and Co-Founder of Allogene

Sastry Chilukuri
Sponsor Speaker

Sastry Chilukuri

Co-CEO at Medidata, a Dassault Systèmes company

George Church

George Church

Professor of Genetics, Blavatnik Institute, Harvard Medical School; Director of HMS NHGRI-Center of Excellence in Genomic Science; Director of the Personal Genome Project; Broad Institute & Wyss Harvard Inst. of Biologically Inspired Engineering

Kevin Conroy

Kevin Conroy

Chief Executive Officer, President, and Chairman of the Board, Exact Sciences

Rachel Cohrs
STAT MODERATOR

Rachel Cohrs

Washington Correspondent, STAT

Joia Crear-Perry, M.D., FACOG

Joia Crear-Perry, M.D., FACOG

Founder & President, National Birth Equity Collaborative

Agnieszka Czechowicz, M.D., Ph.D.

Agnieszka Czechowicz, M.D., Ph.D.

Assistant professor of pediatrics, Department of Pediatrics Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University

Natalie E. Dean, Ph.D.

Natalie E. Dean, Ph.D.

Assistant professor, Department of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University

Giulio F. Draetta M.D., Ph.D.
SPONSOR SPEAKER

Giulio F. Draetta M.D., Ph.D.

Chief Scientific Officer, The University of Texas MD Anderson Cancer Center

Lev Facher
STAT MODERATOR

Lev Facher

Washington Correspondent, STAT

Anthony Fauci, M.D.

Anthony Fauci, M.D.

Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health

Adam Feuerstein
STAT Moderator

Adam Feuerstein

Senior Writer, Biotech, STAT

Nicholas Florko
STAT Moderator

Nicholas Florko

Washington Correspondent, STAT

Damian Garde
STAT Moderator

Damian Garde

National Biotech Reporter, STAT

Gideon Gil
STAT MODERATOR

Gideon Gil

Managing Editor, STAT

Olivia Goldhill
STAT MODERATOR

Olivia Goldhill

Investigative Reporter, STAT

Scott Gottlieb, M.D.

Scott Gottlieb, M.D.

Former FDA Commissioner, Fellow at the American Enterprise Institute, and bestselling author of Uncontrolled Spread

John D. Halamka, M.D., M.S.

John D. Halamka, M.D., M.S.

President, Mayo Clinic Platform

Linda Henry
STAT MODERATOR

Linda Henry

CEO, Boston Globe Media Partners

Matthew Herper
STAT Moderator

Matthew Herper

Senior Writer, Medicine; Editorial Director of Events, STAT

Quita Highsmith, MBA
SPONSOR SPEAKER

Quita Highsmith, MBA

Vice President and Chief Diversity Officer, Genentech

Maia Hightower, M.D., MPH, MBA

Maia Hightower, M.D., MPH, MBA

Chief Medical Information Officer, University of Utah Health

Rob Howard

Rob Howard

Professor of Old Age Psychiatry, UCL Division of Psychiatry

Paul Hudson
Sponsor Speaker

Paul Hudson

CEO, Sanofi

Charles Johnson

Charles Johnson

Founder, 4kira4moms

Andrew Joseph
STAT MODERATOR

Andrew Joseph

General Assignment Reporter, STAT

Ragul Kalluri, M.D., Ph.D.
Sponsor Speaker

Ragul Kalluri, M.D., Ph.D.

Chair of Cancer Biology, The University of Texas MD Anderson Cancer Center

James Kugler
Sponsor Speaker

James Kugler

Chief Digital Officer for Merck KGaA, Darmstadt, Germany; CEO of EMD Digital; Board member, Syntropy

Harlan Levine, M.D.
Sponsor Speaker

Harlan Levine, M.D.

President, Strategy and Business Ventures, City of Hope

Beth Macy

Beth Macy

New York Times-bestselling author and author of Dopesick: Dealers, Doctors, and the Drug Company That Addicted America

John Maraganore, Ph.D.

John Maraganore, Ph.D.

Founding CEO, Alnylam Pharmaceuticals

Linsey Marr, Ph.D.

Linsey Marr, Ph.D.

Professor of Civil and Environmental Engineering, Virginia Tech

Folasade P. May, M.D., Ph.D., M.Phil.

Folasade P. May, M.D., Ph.D., M.Phil.

Assistant Professor of Medicine, University of California Los Angeles

Jessica L. Mega, M.D., MPH

Jessica L. Mega, M.D., MPH

Co-Founder and Chief Medical & Scientific Officer, Verily Life Sciences, Inc.

Mark A. Mintun, M.D.

Mark A. Mintun, M.D.

Senior Vice-President of Neuroscience Research & Development, Eli Lilly and Company; President, Avid Radiopharmaceuticals, Inc.

Megan Molteni
STAT MODERATOR

Megan Molteni

Science Writer, STAT

Stephanie Moquin, Ph.D.

Stephanie Moquin, Ph.D.

Principal Scientist, Novartis Institutes for Biomedical Research

Lauren Nichols

Lauren Nichols

Vice President and Long COVID Patient, BODY POLITIC

Katie Palmer
STAT MODERATOR

Katie Palmer

Health Tech Correspondent, STAT

Paul Perreault
SPONSOR SPEAKER

Paul Perreault

CEO & Managing Director, CSL Limited

Arati Prabhakar, Ph.D.

Arati Prabhakar, Ph.D.

CEO, Actuate; former Director, Defense Advanced Research Projects Agency (DARPA)

Casey Ross
STAT Moderator

Casey Ross

National Technology Correspondent, STAT

Uwe Schoenbeck, Ph.D.
Sponsor Speaker

Uwe Schoenbeck, Ph.D.

Senior Vice President and Chief Scientific Officer, Emerging Science & Innovation (ES&I), Pfizer

Rep. Kurt Schrader

Rep. Kurt Schrader

U.S. House of Representatives; Member of the House Committee on Energy and Commerce

Tara A. Schwetz, Ph.D.

Tara A. Schwetz, Ph.D.

Assistant Director for Biomedical Science Initiatives, Office of Science and Technology Policy, Executive Office of the President

Ramona Sequeira
Sponsor Speaker

Ramona Sequeira

President, US business unit and global portfolio commercialization, Takeda Pharmaceutical Company Limited

Nigam H. Shah, MBBS, Ph.D.

Nigam H. Shah, MBBS, Ph.D.

Professor of Medicine, Stanford University; Associate CIO for Data Science, Stanford Health Care

Kate Sheridan
STAT MODERATOR

Kate Sheridan

General assignment reporter, STAT

Laura Shawver

Laura Shawver

Chief Executive Officer, Silverback Therapeutics

Allen Sills, M.D., FACS

Allen Sills, M.D., FACS

Chief Medical Officer, National Football League

Ed Silverman
STAT MODERATOR

Ed Silverman

Pharmalot Columnist, Senior Writer

Darryl Sleep, M.D.
SPONSOR SPEAKER

Darryl Sleep, M.D.

SVP, Global Medical and Chief Medical Officer, Amgen

Alexander Spinelli
STAT MODERATOR

Alexander Spinelli

Engagement Editor, STAT

Nicholas St. Fleur
STAT Moderator

Nicholas St. Fleur

General Assignment Reporter; Associate Editorial Director of Events, STAT

Danny Strong

Danny Strong

Creator and Showrunner, Dopesick

Darien Sutton, M.D.

Darien Sutton, M.D.

Board certified Emergency Medicine physician

Megan Thielking
STAT MODERATOR

Megan Thielking

Senior News Editor, STAT

Stephen J. Ubl
Sponsor Speaker

Stephen J. Ubl

President and Chief Executive Officer, PhRMA

Congresswoman Lauren Underwood

Congresswoman Lauren Underwood

Co-Founder and co-Chair, Black Maternal Health Caucus

Dame Emma Walmsley

Dame Emma Walmsley

Chief Executive Officer, GlaxoSmithKline

Angela Yen, M. Eng, Ph.D.

Angela Yen, M. Eng, Ph.D.

Director, data and Computational Sciences, Vertex Pharmaceuticals

Agenda

Join us from Nov. 16th to 18th

Here's what we covered - our team brought participants inside the the future of health and the life sciences with probing interviews and lively panels featuring experts from across the industry.

November 16, 2021 - Hybrid

1:00 p.m. ET

Welcome from STAT

Virtual
Rick Berke, co-founder and executive editor, STAT

1:05 p.m. ET
Sponsor Speaker

Opening Remarks

Virtual
Ramona Sequeira, president, US business unit and global portfolio commercialization, Takeda Pharmaceutical Company Limited

1:10 p.m. ET

Pfizer: Vaccines and beyond

Virtual
Albert Bourla, DVM, Ph.D., chairman and chief executive officer, Pfizer Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

Pfizer’s CEO, Albert Bourla, returns to the STAT Summit to reflect on the year that was. As the company continues to lead in Covid-19 vaccine production, he will discuss what’s next — from boosters and beyond.

1:35 p.m. ET

Catching up with Tony Fauci

Virtual
Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health Helen Branswell, senior writer, infectious disease, STAT (moderator)

As the deadly Covid-19 pandemic has dragged on, few voices have been as important as that of Anthony Fauci. He’ll join STAT’s Helen Branswell to discuss the past year and what to expect in the months ahead.

2:05 p.m. ET

Interstitial

Virtual

2:10 p.m. ET
Sponsor Session

Leading Change at Sanofi

Virtual
Paul Hudson, CEO, Sanofi Rick Berke, co-founder and executive editor, STAT (moderator)

Over the past two years, Sanofi has narrowed its focus, re-filled its pipeline of experimental drugs, and used cutting edge technologies across its business. CEO Paul Hudson joins STAT’s Rick Berke to discuss.

2:20 p.m. ET
Sponsor Introduction

Introducing the 2021 STAT Biomedical Innovation Award

Virtual
To be announced

This year's recipient of the STAT Biomedical Innovation award will be announced with an introduction from award sponsor, Pfizer.

Sponsor Introduction
Uwe Schoenbeck, Ph.D., senior vice president and chief scientific officer, emerging science & innovation (ES&I), Pfizer
2:40 p.m. ET

Breaking biotech’s barriers

Virtual
Sangeeta N. Bhatia, M.D., Ph.D., John J. and Dorothy Wilson professor, Massachusetts Institute of Technology; heath sciences & technology / electrical engineering & computer science, Howard Hughes Medical Institute; director, Marble Center for Cancer Nanomedicine at the Koch Institute for Integrated Cancer Research Agnieszka Czechowicz, M.D., Ph.D., assistant professor of pediatrics, Department of Pediatrics Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University Laura Shawver, Ph.D., chief executive officer, Silverback Therapeutics Kate Sheridan, general assignment reporter, STAT (moderator)

Many brilliant women study biology. Why don’t more become professors, entrepreneurs, or CEOs? A panel of women who have made their mark in biotech tell their stories, and talk candidly about the ceilings they had to shatter and they are still banging against.

3:05 p.m. ET

Coffee Break

Virtual

3:20 p.m. ET
Sponsor Speaker

Asking the big questions to drive health equity

Virtual
Quita Highsmith, M.B.A., vice president and chief diversity officer, Genentech

Despite an increased focus on inequities in the health care system, data show that disparities and patient distrust continue to deepen. A reflection on the importance of disrupting the status quo, and collaborating to create holistic solutions that address the systemic barriers at the root of health disparities.

3:25 p.m. ET

Confronting an American tragedy

Virtual
Session Introduction: Congresswoman Lauren Underwood, co-founder and co-chair, Black Maternal Health Caucus Joia Crear-Perry, M.D., FACOG, founder & president, National Birth Equity Collaborative Charles Johnson, Founder, 4kira4moms Nicholas St. Fleur, general assignment reporter, associate editorial director of events, STAT (moderator)

Black women are three times more likely to die during childbirth than white women. The causes are myriad and the solutions are long ignored. A look at the progress that is being made, both in research and at the highest echelons of government.

3:55 p.m. ET

Interstitial

Virtual

4:00 p.m. ET
Sponsor Session

Putting the values back in value-based care

Virtual
Harlan Levine, M.D., president of strategy and business ventures, City of Hope Gideon Gil, managing editor, STAT (moderator)

One of the biggest challenges in health care today is the enormous disparity in access to lifesaving care and leading-edge treatments, especially when it comes to cancer. A discussion on the country’s “value-based” health care ecosystem and the path to making cancer care more accessible.

4:10 p.m. ET

Hypebuster Elisabeth Bik

Virtual
Elisabeth Bik, Ph.D., science integrity consultant Olivia Goldhill, investigative reporter, STAT (moderator)

There is no one better at spotting cases where researchers have modified or faked data involving images — a talent that has led her to speak up against both big name researchers and a biotechnology company. Bik will explain how she does it and share stories from her fight for good science.

4:30 p.m. ET
Sponsor Speaker

Closing Remarks

Virtual
Giulio F. Draetta, M.D., Ph.D., chief scientific officer, The University of Texas MD Anderson Cancer Center

4:35 p.m. ET

Closing from STAT

Virtual

5:30 p.m. ET

In-person program - Registration opens

In-person - Attendee pass only

The in-person program will take place at the BSA Space in downtown Boston, located at 290 Congress Street, 2nd Floor. All in-person attendees will be asked to show a proof of Covid-19 vaccination upon arrival. Masks are required indoors throughout the event and reception. Drinks will be served and outdoor networking space will be available.

6:30 p.m. ET

Program begins - Welcome from STAT

In-person - Attendee pass only
Rick Berke, co-founder and executive editor, STAT

6:35 p.m. ET
Sponsor Speaker

Spotlight Session

In-person - Attendee pass only
Featured speaker to be announced.

6:40 p.m. ET

Fireside chat

In-person - Attendee pass only
John Maraganore, Ph.D., founding CEO, Alnylam Pharmaceuticals Kate Sheridan, general assignment reporter, STAT (moderator)

When John Maraganore became the CEO of Alnylam in 2002, the company’s technology was almost unknown to investors. A Nobel Prize, two decades, and three approved products later, he is retiring. He’ll reflect on his journey and talk about the future.

7:00 p.m. ET

The company builder behind Moderna

In-person - Attendee pass only
Noubar Afeyan, Ph.D., founder and CEO, Flagship Pioneering & co-founder & chairman, Moderna Linda Henry, CEO, Boston Globe Media Partners (moderator)

Under founder Noubar Afeyan, Flagship Pioneering has become a prolific and successful assembly line for biotechnology firms, including Agios, Acceleron, and, of course, Moderna. Hear his thoughts on his journey and the future of biotech.

7:35 p.m. ET

Program concludes - Closing from STAT

In-person - Attendee pass only
Matthew Herper, senior writer, medicine; editorial director of events, STAT

7:35 p.m. ET

Networking reception

In-person - Attendee pass only

Drinks and passed appetizers will be served. Attendees will be asked to indicate their comfort level for networking on their name badge. Outdoor networking space available.

November 17, 2021 - Virtual only

1:00 p.m. ET

Opening remarks

Virtual

1:05 p.m. ET

The long haul: Living with long Covid

Virtual
Lauren Nichols, vice president and Long Covid patient, BODY POLITIC Eric Boodman, general assignment reporter, STAT (moderator)

Lauren Nichols grappled with the effects of long Covid for the past year. She shares her story and why calling attention to how little is still known about this disease is so important.

1:25 p.m. ET
Sponsor Introduction

Introducing the 2021 STAT Wunderkinds

Virtual
Angela Yen, M. Eng, Ph.D., director, data and computational sciences, Vertex Pharmaceuticals Stephanie Moquin, Ph.D., principal scientist, Novartis Institutes for Biomedical Research Megan Thielking, senior news editor, STAT (moderator)

Meet the unheralded heroes of science and medicine.

Sponsor Introduction
Raghu Kalluri, M.D., Ph.D., chair of Cancer Biology, The University of Texas MD Anderson Cancer Center
1:55 p.m. ET

Interstitial

Virtual

2:00 p.m. ET

Can Congress finally tackle drug pricing reform? - Part 1

Virtual
Rep. Kurt Schrader, U.S. House of Representatives; member of the House Committee on Energy and Commerce Rachel Cohrs, Washington correspondent, STAT (moderator)

Bringing down high drug prices is a key part of the Democratic Party’s platform. But how, exactly, to do it? A moderate Democrat gives his view of the state of play.

2:20 p.m. ET
Sponsor Session

The next revolution in cell therapy

Virtual
David Chang, M.D., Ph.D., president, chief executive officer and co-founder, Allogene Megan Thielking, senior news editor, STAT (moderator)

Allogene’s goal is to radically transform cancer treatment. David Chang will join STAT’s Megan Thielking to discuss the development of AlloCAR T products for blood cancers and solid tumors, and their potential to increase patient access while decreasing manufacturing time and costs to the healthcare system.

2:30 p.m. ET

Inside the Biden Administration's plan to change science

Virtual
Arati Prabhakar, Ph.D., CEO, Actuate; former director, Defense Advanced Research Projects Agency (DARPA) Tara A. Schwetz, Ph.D., assistant director for biomedical science initiatives, Office of Science and Technology Policy, Executive Office of the President Lev Facher, Washington correspondent, STAT (moderator) Additional speakers to be announced

A testament to the President’s long-held pledge to “end cancer as we know it,” ARPA-H will aim to bring the deftness and flexibility of DARPA to healthcare research. Will it work?

2:55 p.m. ET

Coffee Break

Virtual

3:10 p.m. ET
Sponsor Speaker

Rebuilding trust and traceability in science

Virtual
James Kugler, Chief Digital Officer for Merck KGaA, Darmstadt, Germany; CEO of EMD Digital; Board member, Syntropy

How do we enable collaboration within and between institutions in a secure and ethical way when the institution and practice of science is up for debate?

3:15 p.m. ET

Artificial Intelligence: The new sheriffs in town

Virtual
John Halamka, M.D., M.S., president, Mayo Clinic Platform Maia Hightower, M.D., MPH, MBA, chief medical information officer, University of Utah Health Nigam Shah, MBBS, Ph.D, professor of medicine, Stanford University; associate CIO for data science, Stanford Health Care Casey Ross, national technology correspondent, STAT (moderator)

These academics are helping AI move out of its Wild West phase. For all the hype, there's relatively little research or oversight setting the bar for how AI should improve patient care. Here are some fixes.

3:50 p.m. ET
Sponsor Session

Policy prescriptions for a better health care system

Virtual
Stephen J. Ubl, president and chief executive officer, PhRMA Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

Three in 10 patients with insurance still face financial barriers when accessing health care and prescription medicines in the United States. Steve Ubl will join Matthew Herper to discuss the biopharma industry’s plans to help build a better health care system that improves access and protects innovation.

4:00 p.m. ET

Airborne?

Virtual
Linsey Marr, Ph.D., professor of civil and environmental engineering, Virginia Tech Megan Molteni, science writer, STAT (moderator)

One of the biggest questions of the pandemic: to what degree is the virus spread in droplets, and to what degree does it spread as aerosols in the air? Here’s what we’re learning about the virus’s spread.

4:25 p.m. ET

Biotech visions with George Church

Virtual
George M. Church, Ph.D., professor of genetics, Blavatnik Institute, Harvard Medical School; director of HMS NHGRI-Center of Excellence in Genomic Science; director of the Personal Genome Project; Broad Institute & Wyss Harvard Inst. of Biologically Inspired Engineering Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

One of the pioneers of both DNA sequencing and gene editing, Church is one of the biggest sources of ideas in the biotech industry. From bringing back the mammoth, or something like it, to using CRISPR to barcode mice, come hear his thoughts on health, science, and what it means to be human.

4:55 p.m. ET

Interstitial

Virtual

5:00 p.m. ET

Pharmalot talks Dopesick

Virtual
Beth Macy, New York Times-bestselling author; author, Dopesick: Dealers, Doctors, and the Drug Company That Addicted America Danny Strong, creator and showrunner, Dopesick Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)

The Hulu series Dopesick delves deep into a crisis STAT knows well: the epidemic of opioids in the U.S. Ed Silverman, STAT’s illustrious and award winning pharma correspondent, will trade notes with director of the series and the author of the bestseller on which it is based

5:25 p.m. ET

Closing remarks

Virtual

November 18, 2021 - Virtual only

12:00 p.m. ET

Breakout Session

Virtual - Attendee pass only
Nicholas Florko, Washington correspondent, STAT Matthew Herper, senior writer, medicine; editorial director of events, STAT Andrew Joseph, general assignment reporter, STAT Megan Molteni, science writer, STAT

This virtual breakout session will provide attendees the opportunity to connect with each other, along with featured speakers and STAT reporters. The session will be exclusive to attendee pass holders, and will take place in a private Zoom meeting room separate from the other public-facing programming.

1:00 p.m. ET

Welcome remarks

Virtual

1:02 p.m. ET

GlaxoSmithKline face the future

Virtual
Dame Emma Walmsley, chief executive officer, GlaxoSmithKline Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

Two different funds say GlaxoSmithKline has huge potential — but perhaps not with its current strategy and management team. CEO Emma Walmsley will take the stage to explain why she believes the path GSK is on is the right one.

1:20 p.m. ET

Race and the future of cancer screening

Virtual
Kevin Conroy, chief executive officer, president, and chairman of the board, Exact Sciences Folasade P. May, M.D., Ph.D., M.Phil., assistant professor of medicine, University of California Los Angeles Nicholas St. Fleur, general assignment reporter; associate editorial director of events, STAT (moderator)

As he turned 30, STAT reporter Nicholas St. Fleur got a colonoscopy. His story provides a window into both the rise of colorectal cancer in young Americans and the disproportionate risk Black people face with the disease. Here, he’ll look at the future of colorectal cancer screening, perhaps even detecting cancer with a blood test.

1:50 p.m. ET

Interstitial

Virtual

1:55 p.m. ET
Sponsor Session

Creating alternatives to surgery

Virtual
Liz Barrett, president and chief executive officer, UroGen Pharma Nicholas St. Fleur, general assignment reporter; associate editorial director of events, STAT (moderator)

An inside look into how alternatives to surgical treatment improve patient care for those with specialty cancers and urological diseases.

2:05 p.m. ET

Outthinking the next pandemic

Virtual
Trevor Bedford, Ph.D, associate professor, vaccine and infectious disease division, Fred Hutchinson Cancer Research Center; affiliate faculty, the University of Washington Helen Branswell, senior writer, infectious disease, STAT (moderator)

Trevor Bedford developed a technique for understanding the family trees of viruses. As SARS-Cov-2 virions flooded the United States, he became a key figure in helping the public understand what was happening and why. Now a MacArthur “genius” grant recipient, he’ll talk about what we need to learn from this pandemic and how to face the next one.

2:55 p.m. ET
Sponsor Speaker

Curing cancer takes a village

Virtual
Teresa Bitetti, president, global oncology business unit, Takeda

Faced with the largest global health crisis of our time, the industry came together to achieve what would have been impossible without partnership. A look at how we can apply the accelerated collaboration witnessed in the wake of Covid-19 to oncology and curing cancer.

3:00 p.m. ET

Coffee Break

Virtual

3:15 p.m. ET

The great reopening: A how-to

Virtual
Blythe Adamson, Ph.D., MPH, founder and epidemiologist, Infectious Economics, LLC; Covid Sports and Society Working Group Allen Sills M.D., FACS, chief medical officer, National Football League Damian Garde, national biotech correspondent, STAT (moderator)

When Covid hit, it was hard to imagine entering stadiums for football and basketball games, packing audiences into Broadway theaters, or holding conferences. Experts who have done it will weigh in on how we can return to these activities while minimizing risks, seizing our lives back from the virus.

3:45 p.m. ET
Sponsor speaker

Speeding clinical trials in Covid-19 and beyond

Virtual
Sastry Chilukuri, Co-CEO at Medidata, a Dassault Systèmes company

The pandemic showed a need for haste and agility in conducting clinical trials. Recognizing that business as usual was insufficient, Medidata partnered with clients to implement innovative ways to plan, start, and oversee studies, as well as to collect evidence.

3:50 p.m. ET

Searching for Alzheimer’s answers

Virtual
Maria Glymour, Sc.D., professor, Department of Epidemiology and Biostatistics, UCSF Rob Howard, professor of old age psychiatry, UCL Division of Psychiatry Mark A. Mintun, M.D., senior vice-president of neuroscience research & development, Eli Lilly and Company; president, Avid Radiopharmaceuticals, Inc. Adam Feuerstein, senior writer, biotech, STAT (moderator)

New medicines that target clumps of amyloid in the brain are reaching the market. What data do we need to evaluate them? A discussion.

4:20 p.m. ET

When biology meets technology

Virtual
Amy P. Abernethy, M.D. Ph.D., president of Clinical Studies Platforms, Verily Life Sciences, Inc.; former Principal Deputy Commissioner, FDA Jessica L. Mega, M.D., MPH, co-founder and chief medical & scientific officer, Verily Life Sciences, Inc. Katie Palmer, health tech correspondent, STAT (moderator)

Verily, an Alphabet company, has been the site of tons of eye-catching projects. But it also seemed to lack focus. The company’s leaders take center stage to discuss the work the company has already done, and what it is doing, to change the nature of clinical trials.

4:45 p.m. ET
Sponsor Session

How do we stop disease before it starts?

Virtual
Darryl Sleep, M.D., senior vice president, Global Medical and chief medical officer, Amgen Rick Berke, co-founder and executive editor, STAT (moderator)

While the current healthcare model focuses on treating and curing illnesses like cancer, heart disease, and osteoporosis, Amgen is advocating for a different approach: one aimed at predicting who is at risk and helping to prevent the impact of serious diseases.

4:55 p.m. ET

From treatments to trending

Virtual
Natalie E. Dean, Ph.D., assistant professor, Department of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University Darien Sutton, M.D., board certified Emergency Medicine physician Scott Gottlieb, M.D., former FDA Commissioner, fellow at the American Enterprise Institute, and bestselling author of Uncontrolled Spread Alexander Spinelli, engagement editor, STAT (moderator)

How does one communicate the fast-moving science of a pandemic to the public? Social media, with its short messages and overheated memes, would seem an odd fit. But these experts have found themselves taking to their feeds to explain hard science.

5:25 p.m. ET

Can Congress finally tackle drug pricing reform? - Part 2

Virtual
Rep. Peter Welch Rachel Cohrs, Washington correspondent, STAT (moderator)

Officials in the House and Senate have spent the fall negotiating how, exactly, to lower drug prices. A key player weighs in on the current situation.

5:45 p.m. ET
Sponsor Speaker

Closing remarks

Virtual
Paul Perreault, CEO & managing director, CSL Limited

5:50 p.m. ET

Closing from STAT

Virtual

Location

Hybrid Event

This year’s STAT Summit had virtual and in-person components. The majority of programming took place virtually, via live-stream. There was an in-person evening event held at the BSA Space in Boston’s Financial District on November 16.

© Mapbox © OpenStreetMap

 

Attend

Thank you for your interest in attending. The 2021 STAT Summit is now complete.


Get our Morning Rounds newsletter

A free, daily guide to news in health and medicine

Sponsors

A special thanks to our partners

Presenting Sponsor

STAT Wunderkinds Sponsor

STAT Biomedical Innovation
Award Sponsor

Premium Sponsors

Supporting Sponsors

Contact

Stay in the loop

Join our email list

Sign up today for summit news and updates

Questions?

Email us any questions or concerns

[email protected]

Terms & Conditions